Impax Laboratories

Impax Laboratories, a subsidiary of Amneal Pharmaceuticals, focuses on the development and production of generic and specialty pharmaceuticals, providing healthcare solutions across diverse therapeutic areas. Impax Laboratories specializes in generic and specialty pharmaceuticals. The company was founded by Dave Matlow and is headquartered in Hayward, US. As part of its strategic evolution, Impax became a subsidiary of Amneal Pharmaceuticals, though specific details of its prior business structure changes are not available.

Impax Laboratories, now operating under Amneal Pharmaceuticals, specializes in the development and manufacture of generic and specialty pharmaceuticals. Their offerings span various therapeutic areas including cardiovascular, central nervous system, infectious disease, and pain management, catering to healthcare professionals and patients. Impax provides alternatives to brand-name medications, ensuring compliance with rigorous quality and safety standards, and serves healthcare providers, wholesalers, and pharmacies throughout North America. Amneal Pharmaceuticals generates revenue through a diverse business model that includes B2B and direct-to-consumer sales channels.

Transactions typically involve partnerships with wholesalers and retail pharmacies, enabling extensive distribution of their pharmaceutical products. The pricing structure is based on negotiated contracts with healthcare providers and pharmacies, featuring volume-based discounts for high-demand products. Flagship offerings in crucial therapeutic areas contribute significantly to the revenue stream, allowing Amneal to engage various pharmaceutical market segments.